nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—SLC5A4—type 2 diabetes mellitus	0.291	0.594	CbGaD
Dapagliflozin—SLC5A2—type 2 diabetes mellitus	0.167	0.341	CbGaD
Dapagliflozin—UGT1A9—Nateglinide—type 2 diabetes mellitus	0.0358	0.118	CbGbCtD
Dapagliflozin—CYP2A6—Rosiglitazone—type 2 diabetes mellitus	0.0212	0.0699	CbGbCtD
Dapagliflozin—UGT2B7—Losartan—type 2 diabetes mellitus	0.0209	0.0691	CbGbCtD
Dapagliflozin—CYP1A2—type 2 diabetes mellitus	0.019	0.0388	CbGaD
Dapagliflozin—CYP3A4—type 2 diabetes mellitus	0.0126	0.0257	CbGaD
Dapagliflozin—ABCB1—Linagliptin—type 2 diabetes mellitus	0.0119	0.0392	CbGbCtD
Dapagliflozin—CYP2C9—Glimepiride—type 2 diabetes mellitus	0.0109	0.036	CbGbCtD
Dapagliflozin—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0106	0.035	CbGbCtD
Dapagliflozin—CYP2C9—Glipizide—type 2 diabetes mellitus	0.00999	0.033	CbGbCtD
Dapagliflozin—CYP2C9—Gliclazide—type 2 diabetes mellitus	0.00928	0.0306	CbGbCtD
Dapagliflozin—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.00809	0.0267	CbGbCtD
Dapagliflozin—CYP2C9—Pioglitazone—type 2 diabetes mellitus	0.00789	0.0261	CbGbCtD
Dapagliflozin—CYP2C9—Chlorpropamide—type 2 diabetes mellitus	0.00789	0.0261	CbGbCtD
Dapagliflozin—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.00766	0.0253	CbGbCtD
Dapagliflozin—CYP2C9—Rosiglitazone—type 2 diabetes mellitus	0.00729	0.024	CbGbCtD
Dapagliflozin—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.00722	0.0238	CbGbCtD
Dapagliflozin—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.00712	0.0235	CbGbCtD
Dapagliflozin—CYP2C9—Tolbutamide—type 2 diabetes mellitus	0.00704	0.0232	CbGbCtD
Dapagliflozin—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.00666	0.022	CbGbCtD
Dapagliflozin—CYP2C9—Valsartan—type 2 diabetes mellitus	0.00644	0.0212	CbGbCtD
Dapagliflozin—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.00637	0.021	CbGbCtD
Dapagliflozin—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.00635	0.021	CbGbCtD
Dapagliflozin—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.00602	0.0199	CbGbCtD
Dapagliflozin—CYP2C9—Nateglinide—type 2 diabetes mellitus	0.00598	0.0197	CbGbCtD
Dapagliflozin—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00581	0.0192	CbGbCtD
Dapagliflozin—CYP2C9—Irbesartan—type 2 diabetes mellitus	0.00574	0.0189	CbGbCtD
Dapagliflozin—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.00547	0.0181	CbGbCtD
Dapagliflozin—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00526	0.0174	CbGbCtD
Dapagliflozin—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.00524	0.0173	CbGbCtD
Dapagliflozin—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00508	0.0168	CbGbCtD
Dapagliflozin—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00459	0.0152	CbGbCtD
Dapagliflozin—CYP1A2—Losartan—type 2 diabetes mellitus	0.0041	0.0135	CbGbCtD
Dapagliflozin—CYP2C9—Glyburide—type 2 diabetes mellitus	0.00404	0.0133	CbGbCtD
Dapagliflozin—ABCB1—Glyburide—type 2 diabetes mellitus	0.00392	0.0129	CbGbCtD
Dapagliflozin—CYP2C9—Losartan—type 2 diabetes mellitus	0.0037	0.0122	CbGbCtD
Dapagliflozin—ABCB1—Losartan—type 2 diabetes mellitus	0.00359	0.0118	CbGbCtD
Dapagliflozin—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00348	0.0115	CbGbCtD
Dapagliflozin—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00334	0.011	CbGbCtD
Dapagliflozin—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00334	0.011	CbGbCtD
Dapagliflozin—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00315	0.0104	CbGbCtD
Dapagliflozin—Canagliflozin—SLC5A2—type 2 diabetes mellitus	0.00296	0.763	CrCbGaD
Dapagliflozin—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00235	0.00776	CbGbCtD
Dapagliflozin—CYP3A4—Losartan—type 2 diabetes mellitus	0.00215	0.00709	CbGbCtD
Dapagliflozin—SLC5A4—nephron tubule—type 2 diabetes mellitus	0.00203	0.106	CbGeAlD
Dapagliflozin—SLC5A4—kidney—type 2 diabetes mellitus	0.00178	0.093	CbGeAlD
Dapagliflozin—SLC5A11—cortex of kidney—type 2 diabetes mellitus	0.00158	0.0823	CbGeAlD
Dapagliflozin—SLC5A2—nephron tubule—type 2 diabetes mellitus	0.00154	0.0802	CbGeAlD
Dapagliflozin—SLC5A2—kidney—type 2 diabetes mellitus	0.00135	0.0705	CbGeAlD
Dapagliflozin—SLC5A2—cortex of kidney—type 2 diabetes mellitus	0.00132	0.0686	CbGeAlD
Dapagliflozin—SLC5A1—nephron tubule—type 2 diabetes mellitus	0.00117	0.0608	CbGeAlD
Dapagliflozin—SLC5A1—cardiovascular system—type 2 diabetes mellitus	0.00105	0.0546	CbGeAlD
Dapagliflozin—SLC5A1—kidney—type 2 diabetes mellitus	0.00102	0.0534	CbGeAlD
Dapagliflozin—UGT2B4—cardiovascular system—type 2 diabetes mellitus	0.000965	0.0503	CbGeAlD
Dapagliflozin—UGT1A9—kidney—type 2 diabetes mellitus	0.000645	0.0336	CbGeAlD
Dapagliflozin—UGT2B4—liver—type 2 diabetes mellitus	0.000597	0.0311	CbGeAlD
Dapagliflozin—UGT2B7—kidney—type 2 diabetes mellitus	0.00052	0.0271	CbGeAlD
Dapagliflozin—Canagliflozin—ABCC2—type 2 diabetes mellitus	0.000504	0.13	CrCbGaD
Dapagliflozin—UGT1A9—liver—type 2 diabetes mellitus	0.000408	0.0213	CbGeAlD
Dapagliflozin—CYP2A6—adipose tissue—type 2 diabetes mellitus	0.000336	0.0175	CbGeAlD
Dapagliflozin—UGT2B7—liver—type 2 diabetes mellitus	0.000328	0.0171	CbGeAlD
Dapagliflozin—CYP2A6—liver—type 2 diabetes mellitus	0.000235	0.0123	CbGeAlD
Dapagliflozin—Canagliflozin—CYP3A4—type 2 diabetes mellitus	0.000223	0.0574	CrCbGaD
Dapagliflozin—Canagliflozin—ALB—type 2 diabetes mellitus	0.000194	0.05	CrCbGaD
Dapagliflozin—CYP1A1—kidney—type 2 diabetes mellitus	0.000193	0.0101	CbGeAlD
Dapagliflozin—CYP2C9—cardiovascular system—type 2 diabetes mellitus	0.00019	0.0099	CbGeAlD
Dapagliflozin—CYP1A1—adipose tissue—type 2 diabetes mellitus	0.000174	0.00907	CbGeAlD
Dapagliflozin—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.000142	0.00739	CbGeAlD
Dapagliflozin—CYP3A4—kidney—type 2 diabetes mellitus	0.000142	0.00739	CbGeAlD
Dapagliflozin—CYP2D6—kidney—type 2 diabetes mellitus	0.000139	0.00727	CbGeAlD
Dapagliflozin—Angina pectoris—Irbesartan—type 2 diabetes mellitus	0.000134	0.00145	CcSEcCtD
Dapagliflozin—Headache—Linagliptin—type 2 diabetes mellitus	0.000134	0.00145	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Glimepiride—type 2 diabetes mellitus	0.000134	0.00145	CcSEcCtD
Dapagliflozin—Skin disorder—Pioglitazone—type 2 diabetes mellitus	0.000133	0.00145	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Sitagliptin—type 2 diabetes mellitus	0.000133	0.00145	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Pioglitazone—type 2 diabetes mellitus	0.000133	0.00144	CcSEcCtD
Dapagliflozin—Infection—Sitagliptin—type 2 diabetes mellitus	0.000132	0.00144	CcSEcCtD
Dapagliflozin—Dizziness—Nateglinide—type 2 diabetes mellitus	0.000132	0.00144	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Ramipril—type 2 diabetes mellitus	0.000132	0.00143	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Ramipril—type 2 diabetes mellitus	0.000131	0.00142	CcSEcCtD
Dapagliflozin—Rash—Acarbose—type 2 diabetes mellitus	0.000131	0.00142	CcSEcCtD
Dapagliflozin—Dermatitis—Acarbose—type 2 diabetes mellitus	0.000131	0.00142	CcSEcCtD
Dapagliflozin—Urticaria—Rosiglitazone—type 2 diabetes mellitus	0.00013	0.00141	CcSEcCtD
Dapagliflozin—Infestation—Metformin—type 2 diabetes mellitus	0.00013	0.00141	CcSEcCtD
Dapagliflozin—Infestation NOS—Metformin—type 2 diabetes mellitus	0.00013	0.00141	CcSEcCtD
Dapagliflozin—Skin disorder—Sitagliptin—type 2 diabetes mellitus	0.00013	0.00141	CcSEcCtD
Dapagliflozin—Influenza—Losartan—type 2 diabetes mellitus	0.000129	0.00141	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Glimepiride—type 2 diabetes mellitus	0.000129	0.0014	CcSEcCtD
Dapagliflozin—Hyponatraemia—Ramipril—type 2 diabetes mellitus	0.000129	0.0014	CcSEcCtD
Dapagliflozin—Nausea—Tolazamide—type 2 diabetes mellitus	0.000128	0.00139	CcSEcCtD
Dapagliflozin—Nausea—Chlorpropamide—type 2 diabetes mellitus	0.000128	0.00139	CcSEcCtD
Dapagliflozin—Hypertension—Bromocriptine—type 2 diabetes mellitus	0.000128	0.00139	CcSEcCtD
Dapagliflozin—Hypersensitivity—Repaglinide—type 2 diabetes mellitus	0.000128	0.00139	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Valsartan—type 2 diabetes mellitus	0.000127	0.00137	CcSEcCtD
Dapagliflozin—Rash—Nateglinide—type 2 diabetes mellitus	0.000126	0.00137	CcSEcCtD
Dapagliflozin—Dermatitis—Nateglinide—type 2 diabetes mellitus	0.000126	0.00137	CcSEcCtD
Dapagliflozin—Angina pectoris—Losartan—type 2 diabetes mellitus	0.000126	0.00137	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Valsartan—type 2 diabetes mellitus	0.000126	0.00137	CcSEcCtD
Dapagliflozin—Urethral disorder—Valsartan—type 2 diabetes mellitus	0.000126	0.00136	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Bromocriptine—type 2 diabetes mellitus	0.000125	0.00136	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Orlistat—type 2 diabetes mellitus	0.000125	0.00136	CcSEcCtD
Dapagliflozin—Hypotension—Glimepiride—type 2 diabetes mellitus	0.000125	0.00136	CcSEcCtD
Dapagliflozin—Urethral disorder—Orlistat—type 2 diabetes mellitus	0.000124	0.00135	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Glipizide—type 2 diabetes mellitus	0.000124	0.00134	CcSEcCtD
Dapagliflozin—CYP1A2—liver—type 2 diabetes mellitus	0.000124	0.00645	CbGeAlD
Dapagliflozin—Angioedema—Glyburide—type 2 diabetes mellitus	0.000124	0.00134	CcSEcCtD
Dapagliflozin—Nausea—Acarbose—type 2 diabetes mellitus	0.000123	0.00134	CcSEcCtD
Dapagliflozin—Constipation—Glipizide—type 2 diabetes mellitus	0.000123	0.00133	CcSEcCtD
Dapagliflozin—CYP1A1—liver—type 2 diabetes mellitus	0.000122	0.00636	CbGeAlD
Dapagliflozin—Malnutrition—Gliclazide—type 2 diabetes mellitus	0.000121	0.00132	CcSEcCtD
Dapagliflozin—ABCB1—retina—type 2 diabetes mellitus	0.000121	0.00632	CbGeAlD
Dapagliflozin—Acute coronary syndrome—Irbesartan—type 2 diabetes mellitus	0.000121	0.00131	CcSEcCtD
Dapagliflozin—Oedema—Bromocriptine—type 2 diabetes mellitus	0.000121	0.00131	CcSEcCtD
Dapagliflozin—Renal failure—Irbesartan—type 2 diabetes mellitus	0.000121	0.00131	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Ramipril—type 2 diabetes mellitus	0.00012	0.00131	CcSEcCtD
Dapagliflozin—Myocardial infarction—Irbesartan—type 2 diabetes mellitus	0.00012	0.0013	CcSEcCtD
Dapagliflozin—Infection—Bromocriptine—type 2 diabetes mellitus	0.00012	0.0013	CcSEcCtD
Dapagliflozin—Pollakiuria—Losartan—type 2 diabetes mellitus	0.00012	0.0013	CcSEcCtD
Dapagliflozin—Urinary tract infection—Irbesartan—type 2 diabetes mellitus	0.000119	0.00129	CcSEcCtD
Dapagliflozin—Nausea—Nateglinide—type 2 diabetes mellitus	0.000119	0.00129	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Pioglitazone—type 2 diabetes mellitus	0.000119	0.00129	CcSEcCtD
Dapagliflozin—Back pain—Gliclazide—type 2 diabetes mellitus	0.000117	0.00127	CcSEcCtD
Dapagliflozin—CYP2C9—liver—type 2 diabetes mellitus	0.000117	0.00612	CbGeAlD
Dapagliflozin—Orthostatic hypotension—Ramipril—type 2 diabetes mellitus	0.000117	0.00127	CcSEcCtD
Dapagliflozin—Skin disorder—Bromocriptine—type 2 diabetes mellitus	0.000117	0.00127	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Glimepiride—type 2 diabetes mellitus	0.000115	0.00125	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Sitagliptin—type 2 diabetes mellitus	0.000115	0.00125	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Metformin—type 2 diabetes mellitus	0.000115	0.00124	CcSEcCtD
Dapagliflozin—ABCB1—nephron tubule—type 2 diabetes mellitus	0.000114	0.00595	CbGeAlD
Dapagliflozin—Constipation—Sitagliptin—type 2 diabetes mellitus	0.000114	0.00124	CcSEcCtD
Dapagliflozin—Urticaria—Glipizide—type 2 diabetes mellitus	0.000114	0.00124	CcSEcCtD
Dapagliflozin—Renal failure—Losartan—type 2 diabetes mellitus	0.000113	0.00123	CcSEcCtD
Dapagliflozin—Hypotension—Bromocriptine—type 2 diabetes mellitus	0.000113	0.00122	CcSEcCtD
Dapagliflozin—Urinary tract infection—Losartan—type 2 diabetes mellitus	0.000112	0.00122	CcSEcCtD
Dapagliflozin—Malnutrition—Valsartan—type 2 diabetes mellitus	0.000112	0.00121	CcSEcCtD
Dapagliflozin—Influenza—Ramipril—type 2 diabetes mellitus	0.000111	0.0012	CcSEcCtD
Dapagliflozin—Angioedema—Gliclazide—type 2 diabetes mellitus	0.000111	0.0012	CcSEcCtD
Dapagliflozin—Oedema—Glyburide—type 2 diabetes mellitus	0.00011	0.0012	CcSEcCtD
Dapagliflozin—Malnutrition—Orlistat—type 2 diabetes mellitus	0.00011	0.0012	CcSEcCtD
Dapagliflozin—Rash—Repaglinide—type 2 diabetes mellitus	0.000109	0.00119	CcSEcCtD
Dapagliflozin—Dermatitis—Repaglinide—type 2 diabetes mellitus	0.000109	0.00118	CcSEcCtD
Dapagliflozin—Urticaria—Pioglitazone—type 2 diabetes mellitus	0.000109	0.00118	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Irbesartan—type 2 diabetes mellitus	0.000109	0.00118	CcSEcCtD
Dapagliflozin—Headache—Repaglinide—type 2 diabetes mellitus	0.000109	0.00118	CcSEcCtD
Dapagliflozin—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.000108	0.00118	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Irbesartan—type 2 diabetes mellitus	0.000108	0.00117	CcSEcCtD
Dapagliflozin—Angina pectoris—Ramipril—type 2 diabetes mellitus	0.000108	0.00117	CcSEcCtD
Dapagliflozin—Urethral disorder—Irbesartan—type 2 diabetes mellitus	0.000108	0.00117	CcSEcCtD
Dapagliflozin—Back pain—Valsartan—type 2 diabetes mellitus	0.000108	0.00117	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Glyburide—type 2 diabetes mellitus	0.000107	0.00116	CcSEcCtD
Dapagliflozin—Back pain—Orlistat—type 2 diabetes mellitus	0.000107	0.00116	CcSEcCtD
Dapagliflozin—Urticaria—Glimepiride—type 2 diabetes mellitus	0.000106	0.00115	CcSEcCtD
Dapagliflozin—Urticaria—Sitagliptin—type 2 diabetes mellitus	0.000106	0.00115	CcSEcCtD
Dapagliflozin—Hypersensitivity—Glipizide—type 2 diabetes mellitus	0.000106	0.00115	CcSEcCtD
Dapagliflozin—Hypertension—Gliclazide—type 2 diabetes mellitus	0.000105	0.00114	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	0.000104	0.00113	CcSEcCtD
Dapagliflozin—Rash—Rosiglitazone—type 2 diabetes mellitus	0.000103	0.00112	CcSEcCtD
Dapagliflozin—Constipation—Bromocriptine—type 2 diabetes mellitus	0.000103	0.00112	CcSEcCtD
Dapagliflozin—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.000103	0.00112	CcSEcCtD
Dapagliflozin—Hypotension—Glyburide—type 2 diabetes mellitus	0.000103	0.00112	CcSEcCtD
Dapagliflozin—Nausea—Repaglinide—type 2 diabetes mellitus	0.000103	0.00112	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Gliclazide—type 2 diabetes mellitus	0.000103	0.00111	CcSEcCtD
Dapagliflozin—Headache—Rosiglitazone—type 2 diabetes mellitus	0.000103	0.00111	CcSEcCtD
Dapagliflozin—ABCB1—cardiovascular system—type 2 diabetes mellitus	0.000102	0.00534	CbGeAlD
Dapagliflozin—Discomfort—Gliclazide—type 2 diabetes mellitus	0.000102	0.00111	CcSEcCtD
Dapagliflozin—Angioedema—Valsartan—type 2 diabetes mellitus	0.000102	0.00111	CcSEcCtD
Dapagliflozin—Malnutrition—Metformin—type 2 diabetes mellitus	0.000102	0.0011	CcSEcCtD
Dapagliflozin—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.000101	0.0011	CcSEcCtD
Dapagliflozin—Angioedema—Orlistat—type 2 diabetes mellitus	0.000101	0.00109	CcSEcCtD
Dapagliflozin—ABCB1—kidney—type 2 diabetes mellitus	0.0001	0.00523	CbGeAlD
Dapagliflozin—ABCB1—pancreas—type 2 diabetes mellitus	9.96e-05	0.00519	CbGeAlD
Dapagliflozin—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	9.85e-05	0.00107	CcSEcCtD
Dapagliflozin—Infection—Gliclazide—type 2 diabetes mellitus	9.84e-05	0.00107	CcSEcCtD
Dapagliflozin—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	9.82e-05	0.00107	CcSEcCtD
Dapagliflozin—ABCB1—cortex of kidney—type 2 diabetes mellitus	9.76e-05	0.00509	CbGeAlD
Dapagliflozin—Acute coronary syndrome—Ramipril—type 2 diabetes mellitus	9.75e-05	0.00106	CcSEcCtD
Dapagliflozin—Renal failure—Ramipril—type 2 diabetes mellitus	9.73e-05	0.00106	CcSEcCtD
Dapagliflozin—Nausea—Rosiglitazone—type 2 diabetes mellitus	9.73e-05	0.00106	CcSEcCtD
Dapagliflozin—Myocardial infarction—Ramipril—type 2 diabetes mellitus	9.7e-05	0.00105	CcSEcCtD
Dapagliflozin—Skin disorder—Gliclazide—type 2 diabetes mellitus	9.62e-05	0.00104	CcSEcCtD
Dapagliflozin—Urinary tract infection—Ramipril—type 2 diabetes mellitus	9.62e-05	0.00104	CcSEcCtD
Dapagliflozin—Urticaria—Bromocriptine—type 2 diabetes mellitus	9.59e-05	0.00104	CcSEcCtD
Dapagliflozin—Malnutrition—Irbesartan—type 2 diabetes mellitus	9.58e-05	0.00104	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Gliclazide—type 2 diabetes mellitus	9.58e-05	0.00104	CcSEcCtD
Dapagliflozin—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	9.54e-05	0.00104	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	9.52e-05	0.00103	CcSEcCtD
Dapagliflozin—Dizziness—Glipizide—type 2 diabetes mellitus	9.48e-05	0.00103	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	9.43e-05	0.00102	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	9.32e-05	0.00101	CcSEcCtD
Dapagliflozin—Discomfort—Orlistat—type 2 diabetes mellitus	9.27e-05	0.00101	CcSEcCtD
Dapagliflozin—Hypotension—Gliclazide—type 2 diabetes mellitus	9.26e-05	0.001	CcSEcCtD
Dapagliflozin—Oedema—Valsartan—type 2 diabetes mellitus	9.1e-05	0.000988	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	9.1e-05	0.000988	CcSEcCtD
Dapagliflozin—Dizziness—Pioglitazone—type 2 diabetes mellitus	9.08e-05	0.000986	CcSEcCtD
Dapagliflozin—Infection—Valsartan—type 2 diabetes mellitus	9.04e-05	0.000981	CcSEcCtD
Dapagliflozin—Rash—Glipizide—type 2 diabetes mellitus	9.04e-05	0.000981	CcSEcCtD
Dapagliflozin—ABCB1—adipose tissue—type 2 diabetes mellitus	9.03e-05	0.00471	CbGeAlD
Dapagliflozin—Dermatitis—Glipizide—type 2 diabetes mellitus	9.03e-05	0.00098	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	8.99e-05	0.000976	CcSEcCtD
Dapagliflozin—Oedema—Orlistat—type 2 diabetes mellitus	8.99e-05	0.000976	CcSEcCtD
Dapagliflozin—Headache—Glipizide—type 2 diabetes mellitus	8.98e-05	0.000975	CcSEcCtD
Dapagliflozin—CYP3A4—liver—type 2 diabetes mellitus	8.95e-05	0.00467	CbGeAlD
Dapagliflozin—Infection—Orlistat—type 2 diabetes mellitus	8.93e-05	0.00097	CcSEcCtD
Dapagliflozin—Dizziness—Glimepiride—type 2 diabetes mellitus	8.85e-05	0.00096	CcSEcCtD
Dapagliflozin—Skin disorder—Valsartan—type 2 diabetes mellitus	8.84e-05	0.00096	CcSEcCtD
Dapagliflozin—Dizziness—Sitagliptin—type 2 diabetes mellitus	8.82e-05	0.000957	CcSEcCtD
Dapagliflozin—CYP2D6—liver—type 2 diabetes mellitus	8.81e-05	0.00459	CbGeAlD
Dapagliflozin—Hypertension—Metformin—type 2 diabetes mellitus	8.77e-05	0.000952	CcSEcCtD
Dapagliflozin—Urticaria—Glyburide—type 2 diabetes mellitus	8.76e-05	0.000951	CcSEcCtD
Dapagliflozin—Angioedema—Irbesartan—type 2 diabetes mellitus	8.76e-05	0.000951	CcSEcCtD
Dapagliflozin—Skin disorder—Orlistat—type 2 diabetes mellitus	8.73e-05	0.000948	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	8.73e-05	0.000948	CcSEcCtD
Dapagliflozin—Back pain—Losartan—type 2 diabetes mellitus	8.72e-05	0.000947	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	8.69e-05	0.000944	CcSEcCtD
Dapagliflozin—Headache—Pioglitazone—type 2 diabetes mellitus	8.6e-05	0.000934	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	8.59e-05	0.000932	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	8.55e-05	0.000928	CcSEcCtD
Dapagliflozin—Discomfort—Metformin—type 2 diabetes mellitus	8.54e-05	0.000927	CcSEcCtD
Dapagliflozin—Nausea—Glipizide—type 2 diabetes mellitus	8.51e-05	0.000924	CcSEcCtD
Dapagliflozin—Hypotension—Valsartan—type 2 diabetes mellitus	8.5e-05	0.000923	CcSEcCtD
Dapagliflozin—Constipation—Gliclazide—type 2 diabetes mellitus	8.47e-05	0.00092	CcSEcCtD
Dapagliflozin—Rash—Glimepiride—type 2 diabetes mellitus	8.43e-05	0.000916	CcSEcCtD
Dapagliflozin—Dermatitis—Glimepiride—type 2 diabetes mellitus	8.43e-05	0.000915	CcSEcCtD
Dapagliflozin—Rash—Sitagliptin—type 2 diabetes mellitus	8.41e-05	0.000913	CcSEcCtD
Dapagliflozin—Dermatitis—Sitagliptin—type 2 diabetes mellitus	8.4e-05	0.000912	CcSEcCtD
Dapagliflozin—Headache—Glimepiride—type 2 diabetes mellitus	8.38e-05	0.00091	CcSEcCtD
Dapagliflozin—Headache—Sitagliptin—type 2 diabetes mellitus	8.35e-05	0.000907	CcSEcCtD
Dapagliflozin—Oedema—Metformin—type 2 diabetes mellitus	8.29e-05	0.0009	CcSEcCtD
Dapagliflozin—Hypertension—Irbesartan—type 2 diabetes mellitus	8.27e-05	0.000898	CcSEcCtD
Dapagliflozin—Angioedema—Losartan—type 2 diabetes mellitus	8.24e-05	0.000895	CcSEcCtD
Dapagliflozin—Infection—Metformin—type 2 diabetes mellitus	8.23e-05	0.000894	CcSEcCtD
Dapagliflozin—Hypersensitivity—Glyburide—type 2 diabetes mellitus	8.13e-05	0.000882	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	8.1e-05	0.00088	CcSEcCtD
Dapagliflozin—Discomfort—Irbesartan—type 2 diabetes mellitus	8.06e-05	0.000875	CcSEcCtD
Dapagliflozin—Skin disorder—Metformin—type 2 diabetes mellitus	8.05e-05	0.000874	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Metformin—type 2 diabetes mellitus	8.01e-05	0.00087	CcSEcCtD
Dapagliflozin—Dizziness—Bromocriptine—type 2 diabetes mellitus	7.98e-05	0.000866	CcSEcCtD
Dapagliflozin—Nausea—Glimepiride—type 2 diabetes mellitus	7.95e-05	0.000862	CcSEcCtD
Dapagliflozin—Nausea—Sitagliptin—type 2 diabetes mellitus	7.92e-05	0.00086	CcSEcCtD
Dapagliflozin—Urticaria—Gliclazide—type 2 diabetes mellitus	7.87e-05	0.000854	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	7.86e-05	0.000853	CcSEcCtD
Dapagliflozin—Body temperature increased—Gliclazide—type 2 diabetes mellitus	7.83e-05	0.00085	CcSEcCtD
Dapagliflozin—Oedema—Irbesartan—type 2 diabetes mellitus	7.82e-05	0.000849	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	7.82e-05	0.000849	CcSEcCtD
Dapagliflozin—Constipation—Valsartan—type 2 diabetes mellitus	7.78e-05	0.000845	CcSEcCtD
Dapagliflozin—Infection—Irbesartan—type 2 diabetes mellitus	7.77e-05	0.000843	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	7.76e-05	0.000843	CcSEcCtD
Dapagliflozin—Hypotension—Metformin—type 2 diabetes mellitus	7.74e-05	0.000841	CcSEcCtD
Dapagliflozin—Malnutrition—Ramipril—type 2 diabetes mellitus	7.73e-05	0.000839	CcSEcCtD
Dapagliflozin—Rash—Bromocriptine—type 2 diabetes mellitus	7.61e-05	0.000826	CcSEcCtD
Dapagliflozin—Dermatitis—Bromocriptine—type 2 diabetes mellitus	7.6e-05	0.000825	CcSEcCtD
Dapagliflozin—Skin disorder—Irbesartan—type 2 diabetes mellitus	7.6e-05	0.000825	CcSEcCtD
Dapagliflozin—Discomfort—Losartan—type 2 diabetes mellitus	7.59e-05	0.000823	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	7.56e-05	0.000821	CcSEcCtD
Dapagliflozin—Headache—Bromocriptine—type 2 diabetes mellitus	7.56e-05	0.000821	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Losartan—type 2 diabetes mellitus	7.36e-05	0.000799	CcSEcCtD
Dapagliflozin—Oedema—Losartan—type 2 diabetes mellitus	7.36e-05	0.000799	CcSEcCtD
Dapagliflozin—Infection—Losartan—type 2 diabetes mellitus	7.31e-05	0.000794	CcSEcCtD
Dapagliflozin—Hypotension—Irbesartan—type 2 diabetes mellitus	7.31e-05	0.000793	CcSEcCtD
Dapagliflozin—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	7.3e-05	0.000792	CcSEcCtD
Dapagliflozin—Urticaria—Valsartan—type 2 diabetes mellitus	7.23e-05	0.000785	CcSEcCtD
Dapagliflozin—Nausea—Bromocriptine—type 2 diabetes mellitus	7.17e-05	0.000778	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	7.15e-05	0.000777	CcSEcCtD
Dapagliflozin—Urticaria—Orlistat—type 2 diabetes mellitus	7.14e-05	0.000776	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Losartan—type 2 diabetes mellitus	7.12e-05	0.000772	CcSEcCtD
Dapagliflozin—Body temperature increased—Orlistat—type 2 diabetes mellitus	7.11e-05	0.000772	CcSEcCtD
Dapagliflozin—Constipation—Metformin—type 2 diabetes mellitus	7.09e-05	0.000769	CcSEcCtD
Dapagliflozin—Angioedema—Ramipril—type 2 diabetes mellitus	7.07e-05	0.000767	CcSEcCtD
Dapagliflozin—Rash—Glyburide—type 2 diabetes mellitus	6.96e-05	0.000755	CcSEcCtD
Dapagliflozin—Dermatitis—Glyburide—type 2 diabetes mellitus	6.95e-05	0.000754	CcSEcCtD
Dapagliflozin—Headache—Glyburide—type 2 diabetes mellitus	6.91e-05	0.00075	CcSEcCtD
Dapagliflozin—Hypotension—Losartan—type 2 diabetes mellitus	6.88e-05	0.000747	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	6.75e-05	0.000733	CcSEcCtD
Dapagliflozin—Hypersensitivity—Valsartan—type 2 diabetes mellitus	6.7e-05	0.000728	CcSEcCtD
Dapagliflozin—Constipation—Irbesartan—type 2 diabetes mellitus	6.69e-05	0.000726	CcSEcCtD
Dapagliflozin—Hypersensitivity—Orlistat—type 2 diabetes mellitus	6.63e-05	0.000719	CcSEcCtD
Dapagliflozin—Urticaria—Metformin—type 2 diabetes mellitus	6.58e-05	0.000715	CcSEcCtD
Dapagliflozin—Nausea—Glyburide—type 2 diabetes mellitus	6.55e-05	0.000711	CcSEcCtD
Dapagliflozin—Dizziness—Gliclazide—type 2 diabetes mellitus	6.55e-05	0.000711	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	6.54e-05	0.00071	CcSEcCtD
Dapagliflozin—Discomfort—Ramipril—type 2 diabetes mellitus	6.5e-05	0.000706	CcSEcCtD
Dapagliflozin—ABCB1—liver—type 2 diabetes mellitus	6.34e-05	0.0033	CbGeAlD
Dapagliflozin—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	6.31e-05	0.000685	CcSEcCtD
Dapagliflozin—Oedema—Ramipril—type 2 diabetes mellitus	6.31e-05	0.000685	CcSEcCtD
Dapagliflozin—Constipation—Losartan—type 2 diabetes mellitus	6.29e-05	0.000683	CcSEcCtD
Dapagliflozin—Rash—Gliclazide—type 2 diabetes mellitus	6.25e-05	0.000678	CcSEcCtD
Dapagliflozin—Dermatitis—Gliclazide—type 2 diabetes mellitus	6.24e-05	0.000677	CcSEcCtD
Dapagliflozin—Urticaria—Irbesartan—type 2 diabetes mellitus	6.21e-05	0.000674	CcSEcCtD
Dapagliflozin—Headache—Gliclazide—type 2 diabetes mellitus	6.21e-05	0.000674	CcSEcCtD
Dapagliflozin—Body temperature increased—Irbesartan—type 2 diabetes mellitus	6.18e-05	0.000671	CcSEcCtD
Dapagliflozin—Skin disorder—Ramipril—type 2 diabetes mellitus	6.13e-05	0.000665	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	6.1e-05	0.000662	CcSEcCtD
Dapagliflozin—Dizziness—Valsartan—type 2 diabetes mellitus	6.02e-05	0.000653	CcSEcCtD
Dapagliflozin—Dizziness—Orlistat—type 2 diabetes mellitus	5.95e-05	0.000646	CcSEcCtD
Dapagliflozin—Hypotension—Ramipril—type 2 diabetes mellitus	5.9e-05	0.00064	CcSEcCtD
Dapagliflozin—Nausea—Gliclazide—type 2 diabetes mellitus	5.88e-05	0.000639	CcSEcCtD
Dapagliflozin—Urticaria—Losartan—type 2 diabetes mellitus	5.85e-05	0.000635	CcSEcCtD
Dapagliflozin—Body temperature increased—Losartan—type 2 diabetes mellitus	5.82e-05	0.000632	CcSEcCtD
Dapagliflozin—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	5.76e-05	0.000626	CcSEcCtD
Dapagliflozin—Rash—Valsartan—type 2 diabetes mellitus	5.74e-05	0.000623	CcSEcCtD
Dapagliflozin—Dermatitis—Valsartan—type 2 diabetes mellitus	5.73e-05	0.000622	CcSEcCtD
Dapagliflozin—Headache—Valsartan—type 2 diabetes mellitus	5.7e-05	0.000619	CcSEcCtD
Dapagliflozin—Rash—Orlistat—type 2 diabetes mellitus	5.67e-05	0.000616	CcSEcCtD
Dapagliflozin—Dermatitis—Orlistat—type 2 diabetes mellitus	5.66e-05	0.000615	CcSEcCtD
Dapagliflozin—Headache—Orlistat—type 2 diabetes mellitus	5.63e-05	0.000612	CcSEcCtD
Dapagliflozin—Dizziness—Metformin—type 2 diabetes mellitus	5.48e-05	0.000595	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	5.45e-05	0.000591	CcSEcCtD
Dapagliflozin—Hypersensitivity—Losartan—type 2 diabetes mellitus	5.42e-05	0.000589	CcSEcCtD
Dapagliflozin—Nausea—Valsartan—type 2 diabetes mellitus	5.41e-05	0.000587	CcSEcCtD
Dapagliflozin—Constipation—Ramipril—type 2 diabetes mellitus	5.4e-05	0.000586	CcSEcCtD
Dapagliflozin—Nausea—Orlistat—type 2 diabetes mellitus	5.34e-05	0.00058	CcSEcCtD
Dapagliflozin—Rash—Metformin—type 2 diabetes mellitus	5.23e-05	0.000567	CcSEcCtD
Dapagliflozin—Dermatitis—Metformin—type 2 diabetes mellitus	5.22e-05	0.000567	CcSEcCtD
Dapagliflozin—Headache—Metformin—type 2 diabetes mellitus	5.19e-05	0.000564	CcSEcCtD
Dapagliflozin—Dizziness—Irbesartan—type 2 diabetes mellitus	5.17e-05	0.000561	CcSEcCtD
Dapagliflozin—Urticaria—Ramipril—type 2 diabetes mellitus	5.01e-05	0.000544	CcSEcCtD
Dapagliflozin—Body temperature increased—Ramipril—type 2 diabetes mellitus	4.99e-05	0.000542	CcSEcCtD
Dapagliflozin—Rash—Irbesartan—type 2 diabetes mellitus	4.93e-05	0.000535	CcSEcCtD
Dapagliflozin—Dermatitis—Irbesartan—type 2 diabetes mellitus	4.93e-05	0.000535	CcSEcCtD
Dapagliflozin—Nausea—Metformin—type 2 diabetes mellitus	4.92e-05	0.000534	CcSEcCtD
Dapagliflozin—Headache—Irbesartan—type 2 diabetes mellitus	4.9e-05	0.000532	CcSEcCtD
Dapagliflozin—Dizziness—Losartan—type 2 diabetes mellitus	4.87e-05	0.000528	CcSEcCtD
Dapagliflozin—Hypersensitivity—Ramipril—type 2 diabetes mellitus	4.65e-05	0.000505	CcSEcCtD
Dapagliflozin—Nausea—Irbesartan—type 2 diabetes mellitus	4.65e-05	0.000504	CcSEcCtD
Dapagliflozin—Rash—Losartan—type 2 diabetes mellitus	4.64e-05	0.000504	CcSEcCtD
Dapagliflozin—Dermatitis—Losartan—type 2 diabetes mellitus	4.64e-05	0.000503	CcSEcCtD
Dapagliflozin—Headache—Losartan—type 2 diabetes mellitus	4.61e-05	0.000501	CcSEcCtD
Dapagliflozin—Nausea—Losartan—type 2 diabetes mellitus	4.37e-05	0.000475	CcSEcCtD
Dapagliflozin—Dizziness—Ramipril—type 2 diabetes mellitus	4.17e-05	0.000453	CcSEcCtD
Dapagliflozin—Rash—Ramipril—type 2 diabetes mellitus	3.98e-05	0.000432	CcSEcCtD
Dapagliflozin—Dermatitis—Ramipril—type 2 diabetes mellitus	3.98e-05	0.000432	CcSEcCtD
Dapagliflozin—Headache—Ramipril—type 2 diabetes mellitus	3.95e-05	0.000429	CcSEcCtD
Dapagliflozin—Nausea—Ramipril—type 2 diabetes mellitus	3.75e-05	0.000407	CcSEcCtD
Dapagliflozin—UGT1A9—Metabolism—ALB—type 2 diabetes mellitus	1.63e-06	1.76e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—HMGCR—type 2 diabetes mellitus	1.63e-06	1.76e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CALM1—type 2 diabetes mellitus	1.61e-06	1.74e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—APOE—type 2 diabetes mellitus	1.61e-06	1.73e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	1.6e-06	1.73e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	1.6e-06	1.72e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ADRA2A—type 2 diabetes mellitus	1.6e-06	1.72e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—APOA1—type 2 diabetes mellitus	1.59e-06	1.71e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SREBF1—type 2 diabetes mellitus	1.58e-06	1.7e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SNAP25—type 2 diabetes mellitus	1.58e-06	1.7e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PSMD6—type 2 diabetes mellitus	1.58e-06	1.7e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	1.57e-06	1.69e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GNB3—type 2 diabetes mellitus	1.57e-06	1.69e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.57e-06	1.69e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SREBF1—type 2 diabetes mellitus	1.57e-06	1.69e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SNAP25—type 2 diabetes mellitus	1.57e-06	1.69e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PSMD6—type 2 diabetes mellitus	1.57e-06	1.69e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SLC2A2—type 2 diabetes mellitus	1.56e-06	1.68e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—HMOX1—type 2 diabetes mellitus	1.56e-06	1.68e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—NOS3—type 2 diabetes mellitus	1.56e-06	1.68e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3R1—type 2 diabetes mellitus	1.56e-06	1.68e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CTGF—type 2 diabetes mellitus	1.55e-06	1.67e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CAT—type 2 diabetes mellitus	1.54e-06	1.66e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CTGF—type 2 diabetes mellitus	1.54e-06	1.66e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—HMGCR—type 2 diabetes mellitus	1.54e-06	1.66e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP2E1—type 2 diabetes mellitus	1.53e-06	1.65e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—MTR—type 2 diabetes mellitus	1.53e-06	1.65e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CPT1A—type 2 diabetes mellitus	1.53e-06	1.65e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—HMGCR—type 2 diabetes mellitus	1.52e-06	1.64e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—SLC2A1—type 2 diabetes mellitus	1.52e-06	1.63e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP1A2—type 2 diabetes mellitus	1.52e-06	1.63e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ADRA2A—type 2 diabetes mellitus	1.5e-06	1.62e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	1.5e-06	1.62e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NAMPT—type 2 diabetes mellitus	1.5e-06	1.62e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	1.5e-06	1.62e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—APOB—type 2 diabetes mellitus	1.5e-06	1.61e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	1.49e-06	1.61e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GCK—type 2 diabetes mellitus	1.49e-06	1.61e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—HBA1—type 2 diabetes mellitus	1.49e-06	1.61e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—LIPC—type 2 diabetes mellitus	1.49e-06	1.61e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ADRA2A—type 2 diabetes mellitus	1.49e-06	1.61e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP11A1—type 2 diabetes mellitus	1.48e-06	1.6e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP3A4—type 2 diabetes mellitus	1.48e-06	1.59e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SLC9A1—type 2 diabetes mellitus	1.46e-06	1.57e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTM1—type 2 diabetes mellitus	1.45e-06	1.57e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GCG—type 2 diabetes mellitus	1.45e-06	1.57e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—SLC2A4—type 2 diabetes mellitus	1.45e-06	1.57e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	1.45e-06	1.56e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	1.45e-06	1.56e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	1.45e-06	1.56e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	1.45e-06	1.56e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP2E1—type 2 diabetes mellitus	1.44e-06	1.56e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CETP—type 2 diabetes mellitus	1.44e-06	1.55e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP2E1—type 2 diabetes mellitus	1.43e-06	1.54e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SLC2A1—type 2 diabetes mellitus	1.43e-06	1.54e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP1A2—type 2 diabetes mellitus	1.43e-06	1.54e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—LPL—type 2 diabetes mellitus	1.43e-06	1.54e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTGS2—type 2 diabetes mellitus	1.43e-06	1.54e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SLC2A1—type 2 diabetes mellitus	1.42e-06	1.53e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP1A2—type 2 diabetes mellitus	1.42e-06	1.53e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PPARG—type 2 diabetes mellitus	1.4e-06	1.51e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ADCY5—type 2 diabetes mellitus	1.4e-06	1.51e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	1.39e-06	1.5e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GPX1—type 2 diabetes mellitus	1.39e-06	1.5e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	1.39e-06	1.5e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP3A4—type 2 diabetes mellitus	1.38e-06	1.49e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	1.37e-06	1.48e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—INS—type 2 diabetes mellitus	1.37e-06	1.48e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	1.37e-06	1.48e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	1.37e-06	1.48e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SLC2A4—type 2 diabetes mellitus	1.36e-06	1.46e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GCG—type 2 diabetes mellitus	1.36e-06	1.46e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CD36—type 2 diabetes mellitus	1.36e-06	1.46e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	1.34e-06	1.45e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PPP2CA—type 2 diabetes mellitus	1.34e-06	1.44e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SNAP25—type 2 diabetes mellitus	1.34e-06	1.44e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PSMD6—type 2 diabetes mellitus	1.34e-06	1.44e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SREBF1—type 2 diabetes mellitus	1.34e-06	1.44e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CTGF—type 2 diabetes mellitus	1.31e-06	1.41e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—HMGCR—type 2 diabetes mellitus	1.3e-06	1.4e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	1.29e-06	1.39e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—MTHFR—type 2 diabetes mellitus	1.29e-06	1.38e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	1.28e-06	1.38e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ADRA2A—type 2 diabetes mellitus	1.27e-06	1.37e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PPARA—type 2 diabetes mellitus	1.26e-06	1.36e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ALB—type 2 diabetes mellitus	1.26e-06	1.36e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	1.25e-06	1.35e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.25e-06	1.35e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	1.25e-06	1.34e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	1.23e-06	1.33e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP2E1—type 2 diabetes mellitus	1.22e-06	1.32e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—AGT—type 2 diabetes mellitus	1.22e-06	1.32e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SLC2A1—type 2 diabetes mellitus	1.21e-06	1.3e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	1.21e-06	1.3e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—NOS3—type 2 diabetes mellitus	1.2e-06	1.3e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3R1—type 2 diabetes mellitus	1.2e-06	1.3e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CALM1—type 2 diabetes mellitus	1.2e-06	1.29e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—APOE—type 2 diabetes mellitus	1.2e-06	1.29e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	1.19e-06	1.29e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—APOA1—type 2 diabetes mellitus	1.18e-06	1.27e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	1.18e-06	1.27e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	1.18e-06	1.27e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	1.18e-06	1.27e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.18e-06	1.27e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP3A4—type 2 diabetes mellitus	1.18e-06	1.27e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	1.17e-06	1.27e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	1.17e-06	1.26e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GNB3—type 2 diabetes mellitus	1.17e-06	1.26e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.17e-06	1.26e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—HMOX1—type 2 diabetes mellitus	1.16e-06	1.25e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	1.16e-06	1.25e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SLC2A4—type 2 diabetes mellitus	1.16e-06	1.25e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GCG—type 2 diabetes mellitus	1.16e-06	1.25e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	1.16e-06	1.25e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	1.16e-06	1.25e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	1.15e-06	1.24e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	1.15e-06	1.24e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	1.15e-06	1.24e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CAT—type 2 diabetes mellitus	1.15e-06	1.24e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	1.14e-06	1.23e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	1.14e-06	1.23e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	1.13e-06	1.21e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	1.12e-06	1.21e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	1.12e-06	1.2e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—APOB—type 2 diabetes mellitus	1.12e-06	1.2e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	1.11e-06	1.2e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	1.11e-06	1.2e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTGS2—type 2 diabetes mellitus	1.1e-06	1.19e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	1.09e-06	1.18e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTM1—type 2 diabetes mellitus	1.09e-06	1.17e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	1.08e-06	1.17e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	1.07e-06	1.16e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	1.07e-06	1.15e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—LPL—type 2 diabetes mellitus	1.07e-06	1.15e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	1.05e-06	1.13e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	1.05e-06	1.13e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ADCY5—type 2 diabetes mellitus	1.04e-06	1.12e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PPARG—type 2 diabetes mellitus	1.04e-06	1.12e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GPX1—type 2 diabetes mellitus	1.04e-06	1.12e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	1.03e-06	1.11e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	1.03e-06	1.11e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	1.03e-06	1.11e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	1.03e-06	1.11e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—INS—type 2 diabetes mellitus	1.02e-06	1.1e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	1.02e-06	1.1e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	1.01e-06	1.09e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CD36—type 2 diabetes mellitus	1.01e-06	1.09e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	1.01e-06	1.09e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	1.01e-06	1.09e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	1e-06	1.08e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PPARGC1A—type 2 diabetes mellitus	1e-06	1.08e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GNB3—type 2 diabetes mellitus	1e-06	1.08e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PPP2CA—type 2 diabetes mellitus	9.99e-07	1.08e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—HMOX1—type 2 diabetes mellitus	9.95e-07	1.07e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	9.83e-07	1.06e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CAT—type 2 diabetes mellitus	9.82e-07	1.06e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	9.75e-07	1.05e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	9.67e-07	1.04e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	9.59e-07	1.03e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—MTHFR—type 2 diabetes mellitus	9.59e-07	1.03e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	9.56e-07	1.03e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	9.53e-07	1.03e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	9.49e-07	1.02e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	9.45e-07	1.02e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	9.44e-07	1.02e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PPARA—type 2 diabetes mellitus	9.41e-07	1.01e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ALB—type 2 diabetes mellitus	9.37e-07	1.01e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	9.34e-07	1.01e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	9.34e-07	1.01e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	9.27e-07	9.99e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	9.19e-07	9.9e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—AGT—type 2 diabetes mellitus	9.11e-07	9.82e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	9.1e-07	9.81e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	9.04e-07	9.74e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	9.01e-07	9.7e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3R1—type 2 diabetes mellitus	8.96e-07	9.66e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—NOS3—type 2 diabetes mellitus	8.96e-07	9.66e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CALM1—type 2 diabetes mellitus	8.96e-07	9.65e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	8.95e-07	9.65e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	8.95e-07	9.65e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—APOE—type 2 diabetes mellitus	8.93e-07	9.62e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	8.91e-07	9.6e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	8.9e-07	9.59e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	8.88e-07	9.57e-06	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—AKT1—type 2 diabetes mellitus	8.83e-07	9.51e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—APOA1—type 2 diabetes mellitus	8.83e-07	9.51e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	8.65e-07	9.32e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	8.54e-07	9.2e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	8.33e-07	8.97e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTGS2—type 2 diabetes mellitus	8.2e-07	8.83e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	8.2e-07	8.83e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—INS—type 2 diabetes mellitus	8.17e-07	8.8e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	8.04e-07	8.66e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	7.85e-07	8.45e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	7.79e-07	8.39e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PPARG—type 2 diabetes mellitus	7.78e-07	8.38e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	7.72e-07	8.31e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	7.72e-07	8.31e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	7.69e-07	8.29e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	7.68e-07	8.28e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	7.66e-07	8.25e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	7.63e-07	8.22e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—INS—type 2 diabetes mellitus	7.63e-07	8.22e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	7.58e-07	8.17e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	7.54e-07	8.13e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	7.49e-07	8.07e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	7.36e-07	7.93e-06	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—AKT1—type 2 diabetes mellitus	7.18e-07	7.73e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	7.16e-07	7.71e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	7.16e-07	7.71e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	7.16e-07	7.71e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	7.05e-07	7.6e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	7.03e-07	7.57e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ALB—type 2 diabetes mellitus	6.99e-07	7.53e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	6.88e-07	7.41e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	6.85e-07	7.38e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	6.75e-07	7.27e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	6.75e-07	7.27e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3R1—type 2 diabetes mellitus	6.69e-07	7.21e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NOS3—type 2 diabetes mellitus	6.69e-07	7.21e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	6.67e-07	7.19e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	6.65e-07	7.16e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	6.59e-07	7.1e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	6.55e-07	7.06e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	6.52e-07	7.02e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	6.33e-07	6.81e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	6.21e-07	6.69e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	6.17e-07	6.65e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTGS2—type 2 diabetes mellitus	6.12e-07	6.59e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	6.01e-07	6.48e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	5.98e-07	6.44e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	5.91e-07	6.37e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	5.89e-07	6.34e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	5.82e-07	6.27e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	5.72e-07	6.16e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	5.72e-07	6.16e-06	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—AKT1—type 2 diabetes mellitus	5.53e-07	5.96e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	5.23e-07	5.63e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	5.13e-07	5.53e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	5.03e-07	5.42e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	4.61e-07	4.97e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	4.41e-07	4.75e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	4.41e-07	4.75e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—AKT1—type 2 diabetes mellitus	4.12e-07	4.44e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	4.03e-07	4.35e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	3.29e-07	3.55e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	3.1e-07	3.34e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—AKT1—type 2 diabetes mellitus	3.07e-07	3.31e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	2.63e-07	2.83e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	2.03e-07	2.18e-06	CbGpPWpGaD
